CRISPR Therapeutics AG (CRSP) Other Operating Expenses (2016 - 2026)

CRISPR Therapeutics AG has reported Other Operating Expenses for 9 years, with the latest figure at $45.9 million in Q1 2026.

• Quarterly Other Operating Expenses fell 20.1% year-over-year to $45.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $368.7 million (up 181.0% YoY) and the FY2025 annual result came in at $309.7 million, up 156.68% from the prior year.
• Other Operating Expenses declined to $45.9 million in Q1 2026 per CRSP's latest filing, from $124.2 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $141.4 million in Q2 2025 and troughed at $6.8 million in Q4 2022.
• A 5-year average of $46.3 million and a median of $42.2 million in 2023 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Other Operating Expenses plunged 78.56% in 2022, then surged 1092.56% in 2025.
• Over 5 years, Other Operating Expenses stood at $6.8 million in 2022, then surged by 193.13% to $20.0 million in 2023, then slumped by 47.92% to $10.4 million in 2024, then soared by 1092.56% to $124.2 million in 2025, then sank by 63.01% to $45.9 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $45.9 million, $124.2 million, and $57.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.